2 results
Approved WMOCompleted
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Approved WMOCompleted
To evaluate the safety and effectiveness of the SINOMED BuMA Supreme Sirolimus-Eluting Coronary Stent System with biodegradable polymer versus the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System through angiographic and clinical…